Erleada Approved in Europe for Castration-resistant Prostate Cancer Patients at High Risk of Metastasis

Erleada Approved in Europe for Castration-resistant Prostate Cancer Patients at High Risk of Metastasis
The European Commission has approved the use of Erleada (apalutamide) for the treatment of men with castration-resistant prostate cancer at high risk of developing metastasis, announced Janssen Oncology, the therapy's developer. The decision follows promising data from a Phase 3 trial (NCT01946204), called SPARTAN, where Erleada treatment reduced the risk of cancer spreading by 72% without affecting quality of life scores. In the U.S., the medicine was approved for a similar indication in February 2018. “Today’s approval of apalutamide is a significant milestone and we are pleased that we can now offer patients with high-risk non-metastatic castration-resistant prostate cancer a new treatment option,” Ivo Winiger-Candolfi, MD, oncology solid tumor therapy area lead for Europe, the Middle East, and Africa at Janssen affiliate Cilag GmbH International, said in a press release. “Bringing medicines to patients at earlier stages of disease is vital, and the approval of apalutamide could mark a step change in how we treat prostate cancer in the future. Crucially, treating patients at this stage could delay the cancer from spreading, a key part of our commitment to patients living with this disease and to their families,” he added. Metastasis is a major cause of complications and death among men with prostate cancer, and investigators have been focusing on th
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *